There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilent (A) and Bioxcel Therapeutics Inc (BTAI) with bullish sentiments.
Agilent (A)
In a report released yesterday, Jack Meehan from Barclays maintained a Buy rating on Agilent, with a price target of $86. The company’s shares opened today at $67.60.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.1% and a 59.8% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agilent with a $86.67 average price target, implying a 28.2% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $85 price target.
See today’s analyst top recommended stocks >>
Bioxcel Therapeutics Inc (BTAI)
In a report released yesterday, Geoff Meacham from Barclays maintained a Buy rating on Bioxcel Therapeutics Inc, with a price target of $16. The company’s shares opened today at $10.76.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.0% and a 54.7% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Bausch Health Companies Inc.
Currently, the analyst consensus on Bioxcel Therapeutics Inc is a Strong Buy with an average price target of $20.67, which is a 92.1% upside from current levels. In a report issued on May 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $25 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
